PCRX News and Press, Pacira BioSciences Inc. From 10/13/22

TAMPA, Fla., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited revenues of $167.5 million for the third quarter of 2022, compa...

Pacira BioSciences ( NASDAQ: PCRX ) is collaborating with Sevāredent Sourcing Solutions to provide expanded access to non-opioid pain drug Exparel for patients undergoing oral and maxillofacial procedures. The partnership with Sevā...

TAMPA, Fla., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Sevāredent Sourcing Solutions, a Group Purchasing Organization (GPO) that creates a competitive advantage for like-minded dental organizations through best-in-class vendor partnerships that drive supply chain value and efficiency, and P...

Pacira BioSciences ( NASDAQ: PCRX ) said its non-opioid drug Exparel met the main goal of a phase 3 trial by showing a statistically significant reduction in pain compared to anesthetic bupivacaine HCl, through 96 hours after a type of toe surgery. The company was e...

-- Second Phase 3 study achieves primary and key secondary endpoints; safely demonstrating statistically significant reductions in postsurgical pain and opioid consumption through 96 hours -- -- Company on track to submit supplemental New Drug Application in first quarter of 202...

Summary Heron addressed a key problem recently - its cash balance and cash burn. The cash raised and cost reductions have significantly extended the cash runway. However, much better growth of Zynrelef is required for the stock to recover in a more meaningful way. Aponvie'...

Pacira BioSciences ( NASDAQ: PCRX ) on Tuesday said the European drug regulator's human medicines committee had recommended expanding the indication for its non-opioid treatment Exparel to include its use in children aged 6 years or older to treat postsurgical pain. The Eu...

TAMPA, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the leading global provider of non-opioid pain management options, announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive op...

Pacira Pharmaceuticals (PCRX) announced positive top line Phase III results for EXPAREL as a single-dose femoral nerve block in the adductor canal for post-surgical regional analgesia in patients undergoing total knee arthroplasty, notes John McCamant, biotech expert and editor The Medical Te...

Pacira BioSciences ( NASDAQ: PCRX ) stated Tuesday that its preliminary net product sales rose 17.7% sequentially during the month to $59.1M for Aug. 2022; up 108% year-over-year. It includes: EXPAREL net product sales, $46.7M; ZILRETTA sales, $9.7M; and iovera° net p...